Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS · Delayed Price · Currency is USD
30.90
+0.50 (1.64%)
Sep 11, 2025, 10:26 AM EDT
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
$654,374
Profits / Employee
$19,999
Market Cap
47.48B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| CytoDyn | 13 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Takeda Pharmaceutical Company News
- 1 day ago - Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit - Business Wire
- 4 days ago - Takeda Pharmaceutical Company Limited (TAK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - Takeda Pharmaceutical Company Limited (TAK) Oveporexton (TAK-861) Investor Call On Phase 3 Narcolepsy Type 1 Data Presented At World Sleep 2025 (Transcript) - Seeking Alpha
- 4 days ago - Takeda Pharmaceutical Company Limited (TAK) Special Call - Slideshow - Seeking Alpha
- 4 days ago - Takeda Pharmaceutical Co Ltd (TAK) Announces Promising Phase 3 Trial Results for Oveporexton in ... - GuruFocus
- 5 days ago - Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025 - Business Wire
- 7 days ago - U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease - Business Wire
- 21 days ago - What's Going On With Takeda Stock On Friday? - Benzinga